{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:30:52Z","timestamp":1782135052439,"version":"3.54.5"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2020YFS0583"],"award-info":[{"award-number":["2020YFS0583"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>To advance blood transfusion safety, the Chinese Haemovigilance Network (CHN) was put into operation in 2018. This report describes the development of the CHN and evaluates its role by analysing reported adverse transfusion reactions (ATRs) from 2018 to 2020.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>All data in this study were obtained from the CHN online reporting platform. A timeline of CHN development is presented, and the activities of CHN\u2010enrolled facilities are analysed by year. The reported ATRs were analysed in detail for ATR types, blood components involved and adherence to case definition, severity and imputability criteria. Incidence rates were calculated and compared with international examples.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During 2018\u20132020, a total of 3061 ATRs were reported through the CHN online reporting system. The rate of reported ATRs in all facilities and the 10 highest reporting facilities was 0.7\u2030 and 1.8\u2030, respectively. When analysed by year, the incidence rate showed an increasing trend from 2018 to 2020. Allergic (68.2%) and febrile non\u2010haemolytic transfusion reaction (27.1%) were the most common. The vast majority of ATRs (92.0%) were not serious, but serious cases of transfusion\u2010associated circulatory overload, transfusion\u2010associated dyspnoea and hypotensive reaction were common. Most (86.0%) of reported cases were definitely or probably associated with transfusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Under\u2010reporting of ATRs occurs in many Chinese hospitals, but the establishment of CHN has increased ATR recognition and management. More effort will be needed in the future to detect transfusion problems and improve transfusion practice in China.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.13291","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T08:57:00Z","timestamp":1652432220000},"page":"1027-1034","source":"Crossref","is-referenced-by-count":9,"title":["Development of the Chinese Haemovigilance Network and reporting of adverse transfusion reactions from 2018 to 2020"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9164-3631","authenticated-orcid":false,"given":"Xue","family":"Tian","sequence":"first","affiliation":[{"name":"Clinical Transfusion Research Center, Institute of Blood Transfusion Chinese Academy of Medical Sciences and Peking Union Medical College  Chengdu People's Republic of China"},{"name":"Key Laboratory of Transfusion Adverse Reactions CAMS  Chengdu People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Kong","sequence":"additional","affiliation":[{"name":"Clinical Transfusion Research Center, Institute of Blood Transfusion Chinese Academy of Medical Sciences and Peking Union Medical College  Chengdu People's Republic of China"},{"name":"Key Laboratory of Transfusion Adverse Reactions CAMS  Chengdu People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Transfusion Research Center, Institute of Blood Transfusion Chinese Academy of Medical Sciences and Peking Union Medical College  Chengdu People's Republic of China"},{"name":"Key Laboratory of Transfusion Adverse Reactions CAMS  Chengdu People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"He","sequence":"additional","affiliation":[{"name":"Clinical Transfusion Research Center, Institute of Blood Transfusion Chinese Academy of Medical Sciences and Peking Union Medical College  Chengdu People's Republic of China"},{"name":"Key Laboratory of Transfusion Adverse Reactions CAMS  Chengdu People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Transfusion Research Center, Institute of Blood Transfusion Chinese Academy of Medical Sciences and Peking Union Medical College  Chengdu People's Republic of China"},{"name":"Key Laboratory of Transfusion Adverse Reactions CAMS  Chengdu People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8173-9656","authenticated-orcid":false,"given":"Zhong","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Transfusion Research Center, Institute of Blood Transfusion Chinese Academy of Medical Sciences and Peking Union Medical College  Chengdu People's Republic of China"},{"name":"Key Laboratory of Transfusion Adverse Reactions CAMS  Chengdu People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CHN Collaborators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"158","article-title":"Haemovigilance: a system to improve the whole transfusion chain","volume":"35","author":"Carneiro\u2010Proietti ABF","year":"2013","journal-title":"Rev Bras Hematol Hemoter"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01442.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16322"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2017.05.007"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12547"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15008"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2017.07.001"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13130"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12492"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002164"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13059"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01313-6"},{"key":"e_1_2_8_14_1","first-page":"30","article-title":"Blood product transfusion in adults: indications, adverse reactions, and modifications","volume":"102","author":"Raval JS","year":"2020","journal-title":"Am Fam Physician"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12918"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16362"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-833988"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12150"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000151349"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003743"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.08.019"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-860809"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2019.05.003"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000001387"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39101084.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2011-0466-OA"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13047"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30891020325.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39101097.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16572"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13291","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.13291","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:55:44Z","timestamp":1692842144000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/vox.13291"],"URL":"https:\/\/doi.org\/10.1111\/vox.13291","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]}}}